Pancreatic Cancer Surveillance in SMAD4 Mutation Carriers

Introduction to Surveillance Guidelines

The International CAPS Consortium guidelines recommend pancreatic surveillance for individuals with SMAD4 mutations who have at least one first-degree relative with pancreatic cancer, starting at age 45-50 years using alternating MRI/MRCP and endoscopic ultrasound (EUS) at 12-month intervals 1, 2
The American Gastroenterological Association suggests that SMAD4 mutations are associated with significantly increased gastric polyposis and gastric cancer risk, with 73% vs 8% gastric polyposis compared to BMPR1A carriers; p<0.001 3

The European Society of Gastrointestinal Endoscopy recommends alternating between MRI/MRCP and EUS for follow-up surveillance, with 12-month intervals if no abnormalities or only non-concerning findings are detected 1, 2
The National Comprehensive Cancer Network suggests that upper gastrointestinal surveillance should start at age 18 years with 1-3 yearly intervals due to significantly elevated gastric cancer risk 3

The American College of Gastroenterology recommends detecting stage I pancreatic cancer confined to the pancreas with negative resection margins as a goal of surveillance 1, 2
The International CAPS Consortium guidelines suggest that all pancreatic surveillance should occur at high-volume centers with multidisciplinary teams experienced in managing high-risk individuals 1, 2